← Back to patent-cliff list
格隆溴铵
Tier C — Watch / tradeGlycopyrronium Bromide
辉瑞
Originator
1961
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：mAChRs
Brand：Enurev、Tovanor Breezhaler、Seebri、Enurev Breezhaler、Cuvposa、Sialanar、Robinul、Seebri Breezhaler
Indications (approved)：流涎、慢性阻塞性肺疾病、十二指肠溃疡、胃溃疡、胃炎、麻醉、消化性溃疡
Regional status
US
批准上市
1961-08-11
EU
批准上市
2012-09-28
China
批准上市
1982-01-01
Japan
批准上市
2012-09-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Glycopyrronium Bromide?
Approved indications include: 流涎, 慢性阻塞性肺疾病, 十二指肠溃疡, 胃溃疡, 胃炎, 麻醉, 消化性溃疡.
When does the Glycopyrronium Bromide patent expire?
No public expiry year is available for Glycopyrronium Bromide yet; this page updates once verified.
How do I get a quote for Glycopyrronium Bromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25